Arabic
Chinese
French
Hindi
Russian
Spanish
End-to-End Plant Design
GMP Plant Design: Where Compliance Meets Efficiency
Regulatory Compliant
Design
USFDA, EU-GMP, WHO-GMP, PIC/S,
CDSCO, TGA compliant layouts.
Formulation
Facilities
Inhalation (MDI, DPI, Nasal Spray & Nebuliser),
Sterile and Non-sterile products.
Greenfield & Brownfield
Projects
Development of new plants, revamp
and expansion of existing facilities.
API Plant
Design
Regulatory compliant
API plant designs.
Product Development
Science that scales. Development that delivers
OINDP Formulations
Development & Tech Transfer
Specialised in Development and
Tech Transfer of OINDP formulations.
Green Propellant
MDI Development
Specialised in designing and developing
MDIs using next-generation green propellants.
Injectables Scale-Up
& Tech Transfer
Scale up & Tech Transfer of Injectables
and Other dosage forms.
Regulatory Dossier
& Compliance
CTD/ACTD dossier preparation,
DMF compilation & deficiency response.
Nitrosamine Risk
Assessment
Critical product safety
criteria.
Technical Advisory
Decisions backed by data. Compliance backed by experience
End-to-End
Technical Guidance
End-to-End technical guidance for
projects from concept to commercialisation.
Compliance & Remediation
Support
Gap Assessment and Remediation for USFDA
483, EU non-compliance, WHO-PQ, CDSCO.
Equipment Selection
& Support
Judicious equipment
selection support.
Technical
Assessment
Tech Assessment
Reports.
Facility
Audits
compliance support.
Frequently Asked Questions
What dosage forms does RN Pharma Consulting specialise in?
Our team has extensive experience in tablets, capsules, injectables, inhalation products, nasal sprays, ophthalmic, and APIs. We specialise operating in niche areas such as inhalation, nasal and injectable products, along with MDI facilities, with both traditional and green propellants.
Why do pharmaceutical companies choose RN Pharma Consulting?
Pharmaceutical companies choose us because of our strong technical expertise, global project experience, and practical implementation approach. We are proactive in our approach and maintain strong work ethics, which has resulted in repeat clientele.
Can RN Pharma Consulting support both API and formulation manufacturing facilities?
Yes. We provide expert consulting for both API manufacturing plant design and formulation plant design, helping pharmaceutical companies develop efficient, scalable, and GMP-compliant facilities from concept through implementation.
How are green propellants different from traditional propellants?
Traditional MDI propellants (like HFA-134a and HFA-227ea) have a high global warming potential (GWP), even though they replaced ozone-depleting CFCs decades ago. Green propellants, such as HFA-152a, are next-generation alternatives with a significantly lower GWP, aimed at reducing the carbon footprint of inhaler products. However, some green propellants are mildly flammable, unlike their predecessors, which changes formulation, handling, and manufacturing requirements.
When do pharmaceutical companies need to transition their MDIs to green propellants?
Regulatory pressure is accelerating this timeline. The EU’s F-Gas Regulation and UK’s parallel framework are phasing down high-GWP HFCs, pushing manufacturers to shift to low-GWP alternatives like HFA-152a and HFO-1234ze well before older propellants are restricted. In the US, the FDA has signalled support for green propellant transitions. Most major inhaler manufacturers are targeting product reformulations and approvals over the next few years, so companies planning new MDI launches or reformulations are increasingly designing for green propellants from the outset rather than retrofitting later.
What are the critical aspects of an injectable technology transfer?
Key aspects include formulation and process comparability, sterility assurance and aseptic process validation, container-closure system compatibility, analytical method transfer and qualification, stability study alignment, and equipment/scale comparability between sending and receiving sites. Robust documentation (batch records, specifications, validation protocols) and regulatory alignment across both sites are equally critical to ensure a smooth, compliant transfer.
Why is expert planning important for injectable facility design?
Injectable manufacturing requires a high level of control over sterility, contamination risk, process flow, and regulatory compliance. Proper planning at the design stage helps avoid costly modifications, operational inefficiencies, and compliance gaps during qualification, validation, and regulatory inspections.
What formulation plant design services does RN Pharma Consulting provide?
Does RN Pharma Consulting provide global pharmaceutical consulting services?
Yes. RN Pharma Consulting has successfully supported clients across 15+ countries with pharmaceutical facility development, product development, and compliance projects. Our global experience in plant designing helps clients meet international regulatory standards and achieve successful project outcomes.
How do formulation plant design services help achieve regulatory compliance?
Our formulation plant design capabilities are developed in alignment with global regulatory standards, including the US FDA, EU GMP, and WHO GMP. We proactively integrate our first-hand experience in plant design to avoid regulatory and technical compliance issues.
Is a green propellant MDI manufacturing facility different from a usual MDI facility?
Yes. Because green propellants like HFA-152a are flammable, facilities need explosion-proof (ATEX-rated) zones, specialized electrical and HVAC systems, inert gas purging, and enhanced fire/gas detection systems that standard HFA-134a/227ea facilities don’t require. Filling lines, storage, and safety protocols are also redesigned to handle these properties safely, making green propellant facilities a distinct engineering investment rather than a simple retrofit.
What are the main types of injectable dosage forms, and how does that affect manufacturing?
Injectables broadly fall into solutions, suspensions, emulsions, and lyophilized (freeze-dried) powders for reconstitution. Each form has different manufacturing needs, lyophilized products require specialized freeze-drying equipment and longer cycle times, while suspensions need homogeneity and particle size control, and emulsions require careful stability management. The dosage form chosen also drives decisions around fill-finish equipment, container-closure systems, and terminal sterilization versus aseptic processing.